Novel calcium sensing receptor ligands: A patent survey

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 5, 2011, Pages 681-698

  Kiefer, Lionel ^a   Leiris, Simon ^a   Dodd, Robert H ^a  

^a CNRS   (France)

Author keywords

Calcilytics; calcimimetics; calcium sensing receptor; hyperparathyroidism; osteoporosis; parathyroid hormone

Indexed keywords

2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; 3,4 DIMETHOXYPHENYL DERIVATIVE; ALPHA METHYLBENZYLAMINE; CALCILYTIC; CALCIMIMETIC AGENT; CALCIUM SENSING RECEPTOR; CINACALCET; FENDILINE; FOSTEO; NPSR 2143; NPSR 467; NPSR 568; PARATHYROID HORMONE[1-34]; PYRAZOLOPYRIMIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; RONACALERET; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPERPARATHYROIDISM; HYPERTHYROIDISM; IN VIVO STUDY; OSTEOPOROSIS; PATENT; REVIEW;

ANIMALS; CALCIMIMETIC AGENTS; HUMANS; HYPERPARATHYROIDISM; LIGANDS; NAPHTHALENES; OSTEOPOROSIS; PATENTS AS TOPIC; RECEPTORS, CALCIUM-SENSING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955077012     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.568479     Document Type: Review

References (110)

1. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001;81:239-97 (Pubitemid 32096177)
2. Pin JP, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 2003;98:325-54 (Pubitemid 36638547)
3. Jingami H, Nakanishi S, Morikawa K. Structure of the metabotropic glutamate receptor. Curr Opin Neurobiol 2003;13:271-8 (Pubitemid 36792238)
4. Jingami H, Nakanishi S, Morikawa K. Structure of the metabotropic glutamate receptor. Curr Opin Neurobiol 2003;13:271-8 (Pubitemid 36792238)
5. 2+-sensing receptor from bovine parathyroid. Nature 1993;366:575-80 (Pubitemid 24035999)
6. 2+ sensing receptor. J Biol Chem 1996;271:19537-45 (Pubitemid 26271631)
7. 2+ sensing receptors: an overview. Cell Calcium 2004;35:183-96 (Pubitemid 38292362)
8. Riccardi D, Park J, Lee WS, et al. Cloning and functional expression of a rat kidney extracellular calcium/ polyvalent cation-sensing receptor. Proc Natl Acad Sci USA 1995;92:131-5
9. Ruat M, Molliver ME, Snowman AM, et al. Calcium sensing receptor: molecular cloning in rat and localization to nerve terminals. Proc Natl Acad Sci USA 1995;92:3161-5
10. Ferry S, Traiffort E, Stinnakre J, et al. Development and adult expression of rat calcium-sensing receptor transcripts in neurons and oligodendrocytes. Eur J Neurosci 2000;12:872-84 (Pubitemid 30168765)
11. Hofer AM, Brown EM. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 2003;4:530-8 (Pubitemid 36773405)
12. Garrett JE, Capuano IV, Hammerland LG, et al. Molecular cloning and functional expression of human parathyroid calcium receptorc DNAs. J Biol Chem 1995;270:12919-25
13. 2+-sensing receptor. J Biol Chem 1996;271:5972-5
14. 2+)-permeable channels through calcium-sensing receptors. J Neurosci Res 1997;47:547-54 (Pubitemid 27106551)
15. Coulombe J, Faure H, Robin B, et al. In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem. Biophys Res Commun 2004;323:1184-90 (Pubitemid 39296549)
16. Steddon SJ, Cunningham J. Calcimimetics and calcilytics - fooling the calcium receptor. The Lancet 2005;365:2237-9
17. Trivedi R, Mithal A, Chattopadhyay N. Recent updates on the calcium-sensing receptor as a drug target. Curr Med Chem 2008;15:178-86 (Pubitemid 351234621)
18. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006;109:339-65 (Pubitemid 43132817)
19. Hebert SC. Therapeutic use of calcimimetics. Annu Rev Med 2006;57:349-64 (Pubitemid 43261995)
20. Chattopadhyay N, Brown EM. Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing. Mol Genet Metab 2006;89:189-202 (Pubitemid 44442994)
21. Wuthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 2007;37:915-22 (Pubitemid 350151180)
22. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol-Renal 2005;288:F253-264 (Pubitemid 40105383)
23. Brown EM, Pollak M, Hebert SC. The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 1998;49:15-29 (Pubitemid 28197438)
24. Nemeth EF. The search for calcium receptor antagonists (calcilytics). J Mol Endocrinol 2002;29:15-21 (Pubitemid 34965743)
25. Gowen M, Stroup GB, Dodds RA, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000;105:1595-604 (Pubitemid 30390310)
26. Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709 (Pubitemid 24016657)
27. Reeve J. PTH: a future role in the management of osteoporosis? J Bone Miner Res 1996;11:440-5
28. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703 (Pubitemid 41127277)
29. 2+ sensing receptor. J Biol Chem 2003;278:49487-94
30. 2+ sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 2004;279:18990-7 (Pubitemid 38623329)
31. 2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. J Biol Chem 2006;281:21558-65 (Pubitemid 44115492)
32. 2+ sensing receptor. J Biol Chem 2007;282:19000-10 (Pubitemid 47100150)
33. Miedlich SU, Gama L, Seuwen K, et al. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J Biol Chem 2004;279:7254-63 (Pubitemid 38248875)
34. 2+ receptor. J Biol Chem 2002;277:18908-13 (Pubitemid 34952451)
35. 2+ receptor, activates an extracellular ligand-binding domain-deleted rhodopsin-like seven-transmembrane structure in the absence of Ca2+. J Biol Chem 2005;280:37013-20 (Pubitemid 41587785)
36. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-5 (Pubitemid 28173250)
37. Fox J, Lowe SH, Petty BA, et al. NPS R-568: a type 2 calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999;290:473-9 (Pubitemid 29344536)
38. 2+ receptor in rats. J Pharmacol Exp Ther 1999;290:480-6 (Pubitemid 29344537)
39. NPS Pharma, Inc. Calcium receptor-active compounds. WO9612697; 1996
40. NPS Pharma, Inc. Calcium receptor-active molecules. US6001884; 1999
41. NPS Pharma, Inc. Calcium receptor-active molecules. US6031003; 2000
42. Ferry S, Chatel B, Dodd RH, et al. Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cells. Biochem Biophys Res Commun 1997;238:866-73 (Pubitemid 27472668)
43. Silverberg SJ, Bone HG, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997;337:1506-10 (Pubitemid 27495776)
44. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7 (Pubitemid 41725117)
45. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1232-7 (Pubitemid 40862116)
46. Moe SM, Cunningham J, Bommer J, et al. Longterm treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005;20:2186-93 (Pubitemid 41510096)
47. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. Clin Endocrinol Metab 2003;88:5644-9 (Pubitemid 38033028)
48. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperthyroidism. J Clin Endocrinol Metab 2005;90:135-41 (Pubitemid 40116646)
49. Ortho-McNeil Pharm, Inc. 1,2-Disubstituted cyclopropanes. US6172091; 2001
50. CNRS (France) Aralkyl-1,2-diamines having calcimimetic activity and preparation mode. WO0134562; 2001
51. CNRS (France) Novel calcium receptor active molecules and method for preparing same. WO0190069; 2001
52. Dauban P, Ferry S, Faure H, et al. N1-Arylsulfonyl-N2-(1-aryl)ethyl-3- phenylpropane-1,2-diamines as novel calcimimetics acting on the calcium sensing receptor. Bioorg Med Chem Lett 2000;10:2001-4 (Pubitemid 30663359)
53. Kessler A, Faure H, Petrel C, et al. N2-Benzyl-N1(1-(1-naphthyl)ethyl)-3- phenylpropane-1,2-diamines andconformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg Med Chem Lett 2004;14:3345-9 (Pubitemid 38624621)
54. Weston AH, Absi M, Ward DT, et al. Evidence in favor of a calcium-sensing receptor in arterial endothelial cells. Studies with Calindol and Calhex 231. Circ Res 2005;97:391-8 (Pubitemid 41216144)
55. 2+-sensing receptors in a rat model of type 2 diabetes. Br J Pharmacol 2008;154:652-62 (Pubitemid 351744940)
56. Wellendorph P, Brauner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene 2004;335:37-46 (Pubitemid 38759751)
57. Harno E, Edwards G, Geraghty AR, et al. Evidence for the presence of GPRC6A receptors in rat mesenteric arteries. Cell Calcium 2008;421:210-19
58. Faure H, Gorojankina T, Rice N, et al. Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor. Cell Calcium 2009;46:323-32
59. Chen W, Bergsman JB, Wang X, et al. Presynaptic external calcium signaling involves the calcium-sensing receptor in neocortical nerve terminals. PloS One 2010;5:e8563
60. Tanabe Seiyaku Co. Arylalkylamines and process for production thereof. WO2005115975; 2005
61. Astellas Pharma, Inc. Pyrrolidine derivative or salt thereof. WO2006123725; 2006
62. Astellas Pharma, Inc. Piperidine derivatives or salts thereof. WO2008059854; 2008
63. Leo Pharma A/S. Novel cyclic hydrocarbon compounds for the treatment of diseases. WO2009065406; 2009
64. Daiichi Sankyo Co. Ltd. Cycloalkylamine derivative. WO2010021351; 2010
65. Amgen, Inc. Calcium receptor modulating agents. WO03099814; 2003
66. Amgen, Inc. Calcium receptor modulating agents. WO2009051718; 2009
67. Amgen, Inc. Calcium receptor modulating agents. WO2008057282; 2008
68. Leo Pharma A/S. Substituted acetylenic compounds useful for the treatment of diseases. WO2008019690; 2008
69. Schering Corp. Use of tricyclic amides for the treatment of disorders of calcium homeostasis. WO2004030669; 2004
70. Aventis Pharma SA. Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use. WO2002059102; 2002
71. Proskelia SAS. Urea derivatives useful as calcium receptor modulators. WO2007060026; 2007
72. Proskelia SAS. Derivatives of urea and related diamines, methods for their manufacture and uses therefor. WO2008006625; 2008
73. Smithkline Beecham Corp. and NPS Pharma, Inc. Calcilytic compounds. WO9845255; 1998 and WO2001008673; 2001
74. Frolik CA, Black EC, Cain RL, et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003;33:372-9 (Pubitemid 37103254)
75. Smithkline Beecham Corp. Calcilytic compounds. WO2002038106; 2002
76. Smithkline Beecham Corp. Calcilytic compounds. WO2004047751; 2004
77. Glaxo Group Ltd. Calcilytic compounds. WO2005030749; 2005
78. Smithkline Beecham Corp. Calcilytic compounds. WO2005077892; 2005
79. Smithkline Beecham Corp. Calcilytic compounds. WO2008077009; 2008
80. Pfizer, Inc. 1,1-(Dimethyl-ethylamino)-2- hydroxy-propoxy]-ethyl?-3- methylbiphenyl- 4-carboxylic acid derivatives as calcium receptor antagonists. WO2010103429; 2010
81. Japan Tobacco, Inc. CaSR antagonist. WO2004094362; 2004
82. Japan Tobacco, Inc. CaSR antagonist. WO2004106280; 2004
83. Bristol-Myers Squibb Co. Novel 2-substituted cyclic amines as calcium sensing modulators. WO2004069793; 2004
84. Bristol-Myers Squibb Co. Substituted piperodines and pyrrolidines as calcium sensing receptor modulators and method. WO2004106295; 2004
85. Bristol-Myers Squibb Co. Novel thiazolidine compounds as calcium sensing receptor modulators. US2004242602; 2004
86. Gavai AV, Vaz RJ, Mikkilineni AB, et al. Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists. Bioorg Med Chem Lett 2005;15:5478-82 (Pubitemid 41562974)
87. Smithkline Beecham Corp. Calcilytic compounds. WO2009055631; 2009
88. Asahi Kasei Pharma Corp. Sulfonamide compound and application thereof.WO2009148052; 2009
89. CNRS (France).Novel diamines having CaSR modulating activity. WO2002012181; 2002
90. Kessler A, Faure H, Roussanne MC, et al. N(1)-Arylsulfonyl-N(2)-(1-(1- naphthyl)ethyl)-1,2-diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. ChemBioChem 2004;5:1131-6 (Pubitemid 39257035)
91. Kessler A, Faure H, Petrel C, et al. N1-Benzoyl-N2-[1-(1-naphthyl)ethyl]- trans-1,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity. J Med Chem 2006;49:5119-28 (Pubitemid 44260208)
92. Novartis AG. Quinazoline derivatives. WO2002102782; 2002
93. Novartis AG. Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone. WO2004056365; 2004
94. Novartis AG. Benzoquinazoline derivatives and their use in treating bone disorders. WO2007020046; 2007
95. Novartis AG. Benzimidazole derivatives. WO2005068433; 2005
96. Novartis AG. Benzimidazole derivatives. WO2007112913; 2007
97. Novartis AG. Pharmaceutical compositions comprising a calcilytic agent. WO2008107390; 2008
98. NPS Pharma, Inc. Quinazolinone compounds as calcilytics. WO2004041755; 2004
99. Shcherbakova I, Balandrin MF, Fox J, et al. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg Med Chem Lett 2005;15:1557-60 (Pubitemid 40312528)
100. Shcherbakova I, Huang G, Geoffroy OJ, et al. Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg Med Chem Lett 2005;15:2537-40 (Pubitemid 40614985)
101. NPS Pharma, Inc. Chromenone compounds as calcilytics. WO2006042007; 2006
102. NPS Pharma, Inc. Pyridazinone compounds as calcilytics. WO2007044796; 2007
103. Smithkline Beecham Corp. Calcilytic compounds. WO2007062370; 2007
104. Pfizer Products, Inc. Pyrido[4,3-d] pyrimidin-4(3H)-one derivatives as calcium receptor antagonists. WO2008041118; 2008
105. Takeda Chemical Industries Ltd. Pyrazolopyrimidine derivative and its application. JP2005239611; 2005
106. Bistol-Myers Squibb Co. Trisubstituted heteroaromatic compounds as calcium receptor modulators. WO2004106296; 2004
107. Ogata H, Ritz E, Odoni G, et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003;14:959-67 (Pubitemid 36359277)
108. Odenwald T, Nakagawa K, Hadtstein C, et al. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 2006;17:655-62
109. Rybczynska A, Lehmann A, Jurska-Jasko A, et al. Hypertensive effect of calcilytic NPS 2143 administration in rats. J Endocrinol 2006;191:189-95 (Pubitemid 44756521)
110. Smajilovic S, Tfelt-Hansen J. Novel role of the calcium-sensing receptor in blood pressure modulation. Hypertension 2008;52:994-1000